The National Institutes of Health (NIH) raised concern about the safety of AstraZeneca’s coronavirus vaccine as the U.S. Food and Drug Administration is weighing whether or not to resume testing in the United States following a global pause in the Phase III trial for safety reasons.
The U.S. Food and Drug Administration said AstraZeneca Plc’s Covid-19 vaccine trial in the United States is still on hold, and the FDA was working with the company to figure out if there was a significant safety issue or not.
AstraZeneca resumed the company’s Covid-19 vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
AstraZeneca resumed British clinical trials of the company’s Covid-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs.
GlaxoSmithKline opened a new $13 million research hub in London focused on artificial intelligence.
Research published in Lancet Oncology analyzed how the risk of death from Covid-19 varies by tumor subtype and patient demographics.
British drugmaker AstraZeneca started testing an antibody-based cocktail for the prevention and treatment of Covid-19, adding to recent signs of progress on possible medical solutions to the disease caused by the novel coronavirus.
According to a new study by Worldwide Partners, the effect that Covid-19 is having on digital health adoption is set to be transformative. The survey that was conducted shows technology is playing a crucial and growing role in mitigating the healthcare crisis, especially via telehealth.
U.S.-based Merck is moving ahead with the company’s $1.3 billion research center in London.
Novavax entered into an agreement to provide the United Kingdom with 60 million doses of the company’s Covid-19 vaccine candidate should NVX-CoV2373 be approved, as well as a late-stage efficacy study in the U.K.
